346 related articles for article (PubMed ID: 25356037)
1. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.
Kaleağasıoğlu F; Berger MR
World J Gastroenterol; 2014 Oct; 20(40):14747-59. PubMed ID: 25356037
[TBL] [Abstract][Full Text] [Related]
2. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review).
Rossi MK; Gnanamony M; Gondi CS
Int J Oncol; 2016 May; 48(5):1765-71. PubMed ID: 26983777
[TBL] [Abstract][Full Text] [Related]
3. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
Xiao Y; Zhang H; Ma Q; Huang R; Lu J; Liang X; Liu X; Zhang Z; Yu L; Pang J; Zhou L; Liu T; Wu H; Liang Z
Cancer Lett; 2019 Oct; 462():51-60. PubMed ID: 31352078
[TBL] [Abstract][Full Text] [Related]
4. Osteonectin regulates the extracellular matrix mineralization of osteoblasts through P38 signaling pathway.
Zhu YS; Gu Y; Jiang C; Chen L
J Cell Physiol; 2020 Mar; 235(3):2220-2231. PubMed ID: 31489629
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
[TBL] [Abstract][Full Text] [Related]
6. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.
Delany AM
Cancer Biol Ther; 2010 Jul; 10(1):65-7. PubMed ID: 20657168
[No Abstract] [Full Text] [Related]
7. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
9. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors.
Ma Y; Chen H; Ma H; Yao Z; Hu J; Ma J; Zhang X; Chen G; Liu Y
Saudi Med J; 2019 Aug; 40(8):755-765. PubMed ID: 31423511
[TBL] [Abstract][Full Text] [Related]
11. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer.
Chang CH; Yen MC; Liao SH; Hsu YL; Lai CS; Chang KP; Hsu YL
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28718842
[TBL] [Abstract][Full Text] [Related]
12. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz J; Ansari D; Sasor A; Andersson R
Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
[TBL] [Abstract][Full Text] [Related]
13. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
14. Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family.
Sullivan MM; Sage EH
Int J Biochem Cell Biol; 2004 Jun; 36(6):991-6. PubMed ID: 15094114
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer.
Munasinghe A; Malik K; Mohamedi F; Moaraf S; Kocher H; Jones L; Hill NJ
Cancer Lett; 2020 May; 477():88-96. PubMed ID: 32113990
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines.
Zhivkova-Galunska M; Adwan H; Eyol E; Kleeff J; Kolb A; Bergmann F; Berger MR
Cancer Biol Ther; 2010 Jul; 10(1):54-64. PubMed ID: 20495387
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
Nagaraju GP; Dontula R; El-Rayes BF; Lakka SS
Carcinogenesis; 2014 May; 35(5):967-73. PubMed ID: 24675529
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin as a therapeutic target for cancer.
Bandopadhyay M; Bulbule A; Butti R; Chakraborty G; Ghorpade P; Ghosh P; Gorain M; Kale S; Kumar D; Kumar S; Totakura KV; Roy G; Sharma P; Shetti D; Soundararajan G; Thorat D; Tomar D; Nalukurthi R; Raja R; Mishra R; Yadav AS; Kundu GC
Expert Opin Ther Targets; 2014 Aug; 18(8):883-95. PubMed ID: 24899149
[TBL] [Abstract][Full Text] [Related]
19. The role of SPARC expression in pancreatic cancer progression and patient survival.
Gundewar C; Sasor A; Hilmersson KS; Andersson R; Ansari D
Scand J Gastroenterol; 2015; 50(9):1170-4. PubMed ID: 25765175
[TBL] [Abstract][Full Text] [Related]
20. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.
Miyoshi K; Sato N; Ohuchida K; Mizumoto K; Tanaka M
Anticancer Res; 2010 Mar; 30(3):867-71. PubMed ID: 20393008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
